News

UCB joins Emerson
Enlarge image

BusinessSwitzerlandBelgium

UCB joins Emerson

10.01.2013 - Belgian UCB S.A has signed a $6.1m contract with Emerson Process Management for UCB’s $228m biotech manufacturing site in Bulle.

Under the terms of the agreement, Emerson will provide automation and operations management systems to construct the first phase of the new microbial production plant. UCB’s 20,000-square-meter facility, which will be one of the largest in Europe, will be the main production centre for Cimzia® (certolizumab pegol), which is used to treat rheumatoid arthritis and Crohn’s disease. Last autumn, UCB opened a €65m mammalian production plant in Belgium.

“The state-of-the-art and largely automated facility at Bulle will be a model for the industry when it opens in 2015,” said Michele Antonelli, UCB executive vice president. “To ensure the project meets its tight build-out schedule, we selected Emerson Process Management for its demonstrated ability to engineer and coordinate fast-track automation projects of this type.”

Emerson’s integrated solution includes its Syncade™ Smart Operations Management Suite, DeltaV™ digital automation system, and AMS Suite predictive maintenance software. Emerson will also provide related engineering services, including design, installation, testing, and commissioning.

„Typical biotech manufacturing can involve thousands of pieces of paper that can affect the ability to produce ‘right-first-time’ batches,” said Lorenzo Zampini, automation project manager. “With Emerson’s integrated operations management and control systems, we can automate the reporting process as well as gain tighter process control for increased productivity and smoother regulatory compliance.”

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/ucb-finds-partner-for-228m-biotech-plant.html

GenericsEUUKHungaryGermanyItalyGreeceAustriaLuxembourgFranceSpain

26.02.2015 It is the first biosimilar monoclonal antibody in many European markets: Mundipharma and Hospira are launching Celltrion’s Remicade generic.

M&AUK

23.02.2015 British drug developer Heptares has been acquired by Japanese biopharma play Sosei for US$400m (€352m).

bioethanolGermanyUKBelgiumFrance

19.02.2015 The price of oil has been sliding for months, and the European bioethanol market is taking it hard. CropEnergies AG has now stopped production at its British unit Ensus UK.

BusinessFranceGermany

17.02.2015 After Christopher Viehbacher’s unceremonious ousting last year, Sanofi has been on the look out for a new CEO. Now, sources say Bayer’s Olivier Brandicourt is set to fill the position.

BusinessUKSwitzerland

12.02.2015 Glaxosmithkline is intent on bolstering its vaccine portfolio further and has bought all shares of Swiss development partner Glycovaxyn.

InvestmentsUKEU

10.02.2015 Interest in biotechnology is on the rise among British investors. Not just one, but two major financiers are planning investment funds in the field.

IVFUKEU

04.02.2015 In a historic move, the UK is set to become the first country to allow the creation of babies with the genetic material of three people – a mother, a father and a female mitochondrial donor.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • SARTORIUS128.00 EUR3.85%
  • CO.DON2.29 EUR3.15%
  • WILEX3.03 EUR2.71%

FLOP

  • SANTHERA96.50 CHF-3.40%
  • PAION2.03 EUR-2.87%
  • ADDEX3.16 CHF-2.47%

TOP

  • WILEX3.03 EUR52.3%
  • SARTORIUS128.00 EUR17.9%
  • FORMYCON16.15 EUR16.2%

FLOP

  • ADDEX3.16 CHF-8.1%
  • SANTHERA96.50 CHF-6.3%
  • BIOFRONTERA1.90 EUR-5.9%

TOP

  • SANTHERA96.50 CHF2387.1%
  • WILEX3.03 EUR413.6%
  • FORMYCON16.15 EUR99.9%

FLOP

  • CYTOS0.33 CHF-89.0%
  • MOLOGEN5.65 EUR-53.5%
  • PAION2.03 EUR-53.0%

No liability assumed, Date: 26.02.2015